Current advances in development of new docetaxel formulations

Zhang, Enhui; Xing, Ronge; Liu, Song; Li, Pengcheng

doi:10.1080/17425247.2019.1583644

Cited by 43 publications

(32 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they identi ed lncRNA EPB41L4A-AS2 as a potential biomarker to evaluate docetaxel sensitivity [51,52]. As previously reported, docetaxel is typically used in the treatment of numerous cancer types, including BC [53]. Docetaxel is a taxane-derived antimitotic chemotherapeutic agent, and its major molecular mechanisms include antagonizing the drug-stabilizing effect on microtubules and limiting the intracellular drug concentration [6,7].…”

Section: Discussionmentioning

confidence: 99%

LncRNA EGFR-AS1 Regulates Breast Cancer Cells Function and Sensitivity to Docetaxel Via the miR-149-5p/ELP5 Axis

Li¹,

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Recently, an increasing number of studies have focused on investigating long non-coding RNAs (lncRNAs) and their role in regulating the progression of various cancer types. However, the biological effects and underlying mechanisms of EGFR-AS1, a typical lncRNA, remain largely unclear in breast cancer.Methods: Differential expression of EGFR-AS1 in breast cancer tissue was analyzed using an integrative database and verified in breast cancer tissue samples and cells via real-time PCR analysis and western blotting analysis. The tumor promoter role of EGFR-AS1 in breast cancer cells was determined through MTT, EDU analysis, colony formation and transwell assays,and the effect of EGFR-AS1 on docetaxel drug sensitivity was examined. We then performed bioinformatic analysis and the dual-luciferase reporter assay to identify the binding sites of EGFR-AS1/miR-149-5p and miR-149-5p/ELP5. Results from western blotting and biological function studies provided insights into whether the EGFR-AS1/miR-149-5p/ELP5 axis regulates breast cancer development in vitro and in vivo. Results: EGFR-AS1 is upregulated in breast cancer tissues and cells and promotes the progression of breast cancer cells both in vitro and in vivo. Moreover, miR-149-5p is downregulated in breast cancer tissues and cell lines. Mechanistically, EGFR-AS1 regulates ELP5 levels by sponging miR-149-5p, thereby affecting cell progression and promoting epithelial-to-mesenchymal transition. Hence, the EGFR-AS1/miR-149-5p/ELP5 axis is involved in breast cancer proliferation, migration, invasion, and resistance to the chemotherapeutic drug, docetaxel, in breast cancer cells. Conclusions: EGFR-AS1 sponges miR-149-5p to affect the expression level of ELP5 ultimately acting as a new tumor promotor in breast cancer. This study provides novel insights into diagnostic and docetaxel-related chemotherapy targets for breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA EGFR-AS1 Regulates Breast Cancer Cells Function and Sensitivity to Docetaxel Via the miR-149-5p/ELP5 Axis

Li¹,

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Fortunately, nanomaterials 44,45 act as precise regulators for the control and release of chemotherapeutic drugs and not only maximize the accuracy of targeting tumour cells but also reduce the adverse reactions caused by drug leakage. DTX 46 is a commonly applied anticancer drug that inhibits physiological microtubule depolymerization and disassembly, but its poor water solubility has restricted its application. After encapsulation of DTX into PLGA nanoparticles (NPs) 47 , improved drug delivery efficiency and reduced systemic side effects were observed.…”

Section: Biomaterial-mediated Chemotherapymentioning

confidence: 99%

Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration

et al. 2021

View full text Add to dashboard Cite

Issues caused by maxillofacial tumours involve not only dealing with tumours but also repairing jaw bone defects. In traditional tumour therapy, the systemic toxicity of chemotherapeutic drugs, invasive surgical resection, intractable tumour recurrence, and metastasis are major threats to the patients’ lives in the clinic. Fortunately, biomaterial-based intervention can improve the efficiency of tumour treatment and decrease the possibility of recurrence and metastasis, suggesting new promising antitumour therapies. In addition, maxillofacial bone tissue defects caused by tumours and their treatment can negatively affect the physiological and psychological health of patients, and investment in treatment can result in a multitude of burdens to society. Biomaterials are promising options because they have good biocompatibility and bioactive properties for stimulation of bone regeneration. More interestingly, an integrated material regimen that combines tumour therapy with bone repair is a promising treatment option. Herein, we summarized traditional and biomaterial-mediated maxillofacial tumour treatments and analysed biomaterials for bone defect repair. Furthermore, we proposed a promising and superior design of dual-functional biomaterials for simultaneous tumour therapy and bone regeneration to provide a new strategy for managing maxillofacial tumours and improve the quality of life of patients in the future.

show abstract

“…Another taxol-derived agent with antimitotic activity is docetaxel (DTX). It is active against various cancers such as prostate cancer, metastatic glioblastoma, metastatic breast cancer and lung cancer [ 69 ]. Frequent phenomena of resistance limit its use, linked above all to the overexpression of the drug’s efflux pumps.…”

Section: Application Of Calixarene On Cancer Therapymentioning

confidence: 99%

Role of Calixarene in Chemotherapy Delivery Strategies

et al. 2021

View full text Add to dashboard Cite

Since cancer is a multifactorial disease with a high mortality rate, the study of new therapeutic strategies is one of the main objectives in modern research. Numerous chemotherapeutic agents, although widely used, have the disadvantage of being not very soluble in water or selective towards cancerous cells, with consequent side effects. Therefore, in recent years, a greater interest has emerged in innovative drug delivery systems (DDSs) such as calixarene, a third-generation supramolecular compound. Calixarene and its water-soluble derivatives show good biocompatibility and have low cytotoxicity. Thanks to their chemical–physical characteristics, calixarenes can be easily functionalized, and by itself can encapsulate host molecules forming nanostructures capable of releasing drugs in a controlled way. The encapsulation of anticancer drugs in a calixarene derivate improves their bioavailability and efficacy. Thus, the use of calixarenes as carriers of anticancer drugs could reduce their side effects and increase their affinity towards the target. This review summarizes the numerous research advances regarding the development of calixarene nanoparticles capable of encapsulating various anticancer drugs.

show abstract

Current advances in development of new docetaxel formulations

Cited by 43 publications

References 105 publications

LncRNA EGFR-AS1 Regulates Breast Cancer Cells Function and Sensitivity to Docetaxel Via the miR-149-5p/ELP5 Axis

LncRNA EGFR-AS1 Regulates Breast Cancer Cells Function and Sensitivity to Docetaxel Via the miR-149-5p/ELP5 Axis

Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration

Role of Calixarene in Chemotherapy Delivery Strategies

Contact Info

Product

Resources

About